Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 4/2013

01.08.2013 | Note

In vitro antifungal drug susceptibilities of Penicillium marneffei from China

verfasst von: Donghua Liu, Ling Liang, Jimin Chen

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Penicillium marneffei infections in immunocompromised patients are often fatal, but early treatment with appropriate antifungal agents may have a good prognosis. To select drugs for treating P. marneffei infection in Southern China, the susceptibilities of antifungal agents against P. marneffei isolates were evaluated. Twenty-five strains of P. marneffei were isolated from patients from 2008 to 2010 in Guangxi Province of China, and 14 strains were isolated from bamboo rats. The activity of voriconazole, fluconazole, itraconazole, terbinafine, and amphotericin B on the isolates was assessed by MIC analysis. Voriconazole MIC against strains of P. marneffei ranged from 0.004 to 0.25 mg/l, and it had the lowest MIC (geometric mean values, 0.04 mg/l) in comparison to the other antifungal agents. The MICs of other antifungal agents, in order of lowest to highest, were as follows: itraconazole, terbinafine, amphotericin B, and fluconazole. The results show voriconazole and itraconazole are active against P. marneffei isolates in vitro, and terbinafine may have unrealized usefulness in the treatment of infections caused by this yeast form.
Literatur
1.
Zurück zum Zitat Samson RA, Yilmaz N, Houbraken J, Spierenburg H, Seifert KA, Peterson SW, et al. Phylogeny and nomenclature of the genus Talaromyces and taxa accommodated in Penicillium subgenus Biverticillium. Stud Mycol. 2011;70:159–83.CrossRefPubMed Samson RA, Yilmaz N, Houbraken J, Spierenburg H, Seifert KA, Peterson SW, et al. Phylogeny and nomenclature of the genus Talaromyces and taxa accommodated in Penicillium subgenus Biverticillium. Stud Mycol. 2011;70:159–83.CrossRefPubMed
2.
Zurück zum Zitat Ustianowski AP, Sieu TP, Day JN. Penicillium marneffei infection in HIV. Curr Opin Infect Dis. 2008;21:31–6.CrossRefPubMed Ustianowski AP, Sieu TP, Day JN. Penicillium marneffei infection in HIV. Curr Opin Infect Dis. 2008;21:31–6.CrossRefPubMed
3.
Zurück zum Zitat Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110.CrossRefPubMed Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110.CrossRefPubMed
4.
Zurück zum Zitat McGinnis MR, Nordoff NG, Ryder NS, Nunn GB. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei. Antimicrob Agents Chemother. 2000;44:1407–8.CrossRefPubMed McGinnis MR, Nordoff NG, Ryder NS, Nunn GB. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei. Antimicrob Agents Chemother. 2000;44:1407–8.CrossRefPubMed
5.
Zurück zum Zitat Wong SS, Ho TY, Ngan AH, Woo PC, Que TL, Yuen KY. Biotyping of Penicillium marneffei reveals concentration-dependent growth inhibition by galactose. J Clin Microbiol. 2001;39:1416–21.CrossRefPubMed Wong SS, Ho TY, Ngan AH, Woo PC, Que TL, Yuen KY. Biotyping of Penicillium marneffei reveals concentration-dependent growth inhibition by galactose. J Clin Microbiol. 2001;39:1416–21.CrossRefPubMed
6.
Zurück zum Zitat John HR, Barbara DA, David A, Beth AS, Steven DB, Vishnu C, et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. Second edition. M38-A2. Clin Lab Stand Inst. 2008;28(16):1–35. John HR, Barbara DA, David A, Beth AS, Steven DB, Vishnu C, et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. Second edition. M38-A2. Clin Lab Stand Inst. 2008;28(16):1–35.
7.
Zurück zum Zitat Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997;41:841–3.PubMed Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997;41:841–3.PubMed
8.
Zurück zum Zitat Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother. 2004;48:1912–5.CrossRefPubMed Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother. 2004;48:1912–5.CrossRefPubMed
9.
Zurück zum Zitat Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993;37:2407–11.CrossRefPubMed Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993;37:2407–11.CrossRefPubMed
10.
Zurück zum Zitat Sirisanthana T, Supparatpinyo K, Nelson KE, et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:1107–10.CrossRefPubMed Sirisanthana T, Supparatpinyo K, Nelson KE, et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:1107–10.CrossRefPubMed
11.
Zurück zum Zitat Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000;12:463–70.PubMed Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000;12:463–70.PubMed
12.
Zurück zum Zitat Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg. 2007;77:350–3.PubMed Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg. 2007;77:350–3.PubMed
13.
Zurück zum Zitat Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother. 2002;46:2219–28.CrossRefPubMed Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother. 2002;46:2219–28.CrossRefPubMed
14.
Zurück zum Zitat Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother. 1998;41:59–65.CrossRefPubMed Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother. 1998;41:59–65.CrossRefPubMed
15.
Zurück zum Zitat Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother. 2002;50:189–94.CrossRefPubMed Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother. 2002;50:189–94.CrossRefPubMed
Metadaten
Titel
In vitro antifungal drug susceptibilities of Penicillium marneffei from China
verfasst von
Donghua Liu
Ling Liang
Jimin Chen
Publikationsdatum
01.08.2013
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 4/2013
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0511-7

Weitere Artikel der Ausgabe 4/2013

Journal of Infection and Chemotherapy 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.